# US 2019/0169638 A1 · Enhanced sleeping beauty transposons, kits and methods of transpositon

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169638 A1
- Document ID: US20190169638A1
- Status: Published application
- Kind: A1
- Application number: 16/085,012
- Filed: 2017-03-15
- Published: 2019-06-06
- Earliest claimed: 2016-03-15
- Assignees: Max-DelbrüCk-Centrum FüR Molekulare Medizin In Der Helmholtz-Gemeinschaft
- Applicants: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
- Inventors: Zsuzsanna IZSVÁK; Zoltán IVICS; Christopher KAUFMANN; Suneel NARAYANAVARI
- Web page: https://patentgrep.com/patent/US20190169638A1

## CPC

- C12N 15/90: Stable introduction of foreign DNA into chromosome
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- C12N 2800/90: Vectors containing a transposable element
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to enhanced Sleeping Beauty-type transposons and methods of transposition. In particular the invention relates to a polynucleotide comprising a cargo nucleic acid flanked by a left and a right inverted repeat/direct repeat (IR/DR), wherein IR/DRs, having specific sequences, are recognized by a Sleeping Beauty transposase protein and the polynucleotide is capable of integrating into the DNA of a cell. The invention also relates to a kit for transposing a nucleic acid comprising said polynucleotide as well as to further components such as co-factors of transposition capable of depleting a component of the FACT (facilitates chromatin transcription) complex, namely, SSRP1 and/or SUPT16H/SPT16, or an inhibitor of cathepsin selected from the group comprising H,S,V, and L; or a cofactor capable of depleting or inhibiting HSP90; or a factor temporally arresting cells cell cycle in cell cycle phase G0/G1, G1/S, or G2/M; or a factor inhibiting the ubiquitination of PCNA, or cells wherein these components have been knocked down or inhibited,or the cell cyle arrested in any of said stages. Alternatively or additionally, the kit may comprise as a co-factor of transposition an agent capable of increasing concentration and/or signaling of ATR or a cell wherein concentrationand/or signaling of ATR are increased. The invention further provides methods using said transposon polynucleotide as well as host cells and pharmaceutical compositions. It also relates to use of said co-factors of transposition or specific cells for enhancing transposition efficiencies, e.g., for preparing genetically modified nucleic acids or cells.

## Claims

### Claim 1

A polynucleotide or the complementary polynucleotide thereof comprising a transposon comprising a cargo nucleic acid flanked by a left and a right inverted repeat/direct repeat (IR/DR), wherein
(i) the transposon is capable of being mobilized by a Sleeping Beauty transposase protein;
(ii) the left IR/DR comprises an outer left DR motif and an inner left DR motif, wherein the outer left DR motif comprises the nucleotide sequence of SEQ ID NO:1 and the inner left DR motif comprises the nucleotide sequence of SEQ ID NO: 2; and
(iii) the right IR/DR comprises an outer right DR motif and an inner right DR motif, wherein the outer right DR motif comprises a reverse complement of the nucleotide sequence of SEQ ID NO:1 and the inner right DR motif comprises a reverse complement of the nucleotide sequence of SEQ ID NO: 2.

### Claim 2 (depends on 1)

The polynucleotide of claim 1, wherein the outer left DR motif comprises the nucleotide sequence of SEQ ID NO: 3 and/or the outer right DR motif comprises a reverse complement of the nucleotide sequence of SEQ ID NO: 4.

### Claim 3 (depends on 1)

The polynucleotide of claim 1, wherein the inner left DR motif comprises the nucleotide sequence of SEQ ID NO: 5 and/or the inner right DR motif comprises a reverse complement of the nucleotide sequence of SEQ ID NO: 6.

### Claim 4 (depends on 1)

The polynucleotide of claim 1, wherein the left IR/DR comprises a HDR region capable of functioning as an enhancer comprising the nucleotide sequence of SEQ ID NO:7 between the outer DR and inner DR, wherein, optionally, the right IR/DR also comprises reverse complement of said HDR region.

### Claim 5 (depends on 1)

The polynucleotide of claim 1, wherein the left IR/DR comprises the nucleotide sequence selected from the group consisting of SEQ ID NO: 8 and SEQ ID NO:9.

### Claim 6 (depends on 1)

The polynucleotide of claim 1, wherein the right IR/DR comprises the reverse complement nucleotide sequence selected from the group consisting of SEQ ID NO: 10, SEQ ID NO:11, SEQ ID NO: 12 and SEQ ID NO: 13.

### Claim 7 (depends on 1)

The polynucleotide of claim 1, wherein the cargo nucleic acid comprises an open reading frame operably linked to a promotor, wherein the open reading frame preferably encodes a T-cell receptor construct or a fragment thereof.

### Claim 8 (depends on 1)

The polynucleotide of claim 1, wherein the polynucleotide is a vector selected from the group consisting of
(i) a viral vector selected from the group comprising an adenoviral, adeno-associated viral, lentiviral, retroviral, herpes simplex viral, baculovirus, Epstein-Barr viral, and poxvirus vector; or
(ii) a non-viral vector selected from the group comprising a plasmid, a minicircle, a pFAR vector or a virosome.

### Claim 9 (depends on 1)

A kit for transposing a nucleic acid, wherein the kit comprises
(i) the polynucleotide of claim 1;
(ii) (a) a Sleeping Beauty transposase protein or (b) a nucleic acid encoding a Sleeping Beauty transposase protein; and
(iii) optionally, at least one cofactor selected from the group comprising
(A) a cofactor capable of depleting a component of the FACT complex selected from the group consisting of SSRP1 and SUPT16H/SPT16;
(B) an inhibitor of cathepsin selected from the group comprising H,S,V, and L;
(C) a cofactor capable of depleting or inhibiting HSP90;
(D) a factor temporally arresting cells cell cycle in cell cycle phase G0/G1, G1/S, or G2/M; and
(E) a factor inhibiting the ubiquitination of PCNA;
(F) an agent capable of increasing concentration and/or signaling of ATR,
wherein said cofactor is selected from the group comprising a small molecule, siRNA and miRNA,
or a cell wherein
(AA) said component of the FACT complex; and/or
(BB) said cathepsin; and/or
(CC) said HSP90, is knocked down; and/or
(DD) the cell cycle is temporally arrested in cell cycle phase G0/G1, G1/S, or G2/M; and/or
(EE) the ubiquitination of PCNA is inhibited; and/or
(FF) concentration and/or signaling of ATR is increased.

### Claim 10 (depends on 9)

A method of producing a recombinant nucleic acid, comprising contacting a target nucleic acid comprising a recognition sequence for a Sleeping Beauty transposase with the components of the kit of claim 9.

### Claim 11 (depends on 9)

A method of producing a transfected cell, wherein the method comprises introducing into said cell the components of the kit of claim 9, wherein the method preferably comprises electroporating the cells.

### Claim 12 (depends on 1)

The polynucleotide of claim 1, wherein the Sleeping Beauty transposase is hyperactive transposase SB100X.

### Claim 13 (depends on 1, 7)

A host cell comprising the polynucleotide of claim 1, wherein, preferably, the host cell is a T-cell suitable for adoptive T cell transfer which comprises the polynucleotide of claim 7.

### Claim 14 (depends on 13)

A pharmaceutical composition comprising the host cell of claim 13.

### Claim 15 (depends on 1)

A use of at least one cofactor or agent selected from the group consisting of
(A) a cofactor capable of depleting a component of the FACT complex selected from the group consisting of SSRP1 and SUPT16H/SPT16;
(B) an inhibitor of cathepsin selected from the group comprising F, H, L, S, and V;
(C) a cofactor capable of depleting or inhibiting HSP90;
(D) a factor temporally arresting cells cell cycle in cell cycle phase G0/G1, G1/S, or G2/M; and
(E) a factor inhibiting the ubiquitination of PCNA; and
(F) an agent capable of increasing concentration and/or signaling of ATR, wherein the cofactor preferably is capable of depleting a component of the FACT complex,
wherein the cofactor is selected from the group comprising a small molecule, an antibody, siRNA and miRNA, or
use of a cell wherein
(AA) said component of the FACT complex;
(BB) said cathepsin; and/or
(CC) said HSP90, is knocked down; and/or
(DD) the cell cycle is temporally arrested in cell cycle phase G0/G1, G1/S, or G2/M, and/or
(EE) the ubiquitination of PCNA is inhibited; and/or
(FF) concentration and/or signaling of ATR is increased
for preparing a recombinant polynucleotide or a recombinant cell comprising a recombinant polynucleotide by transposition of a transposon such as a Sleeping Beauty transposon, wherein the transposon preferably is the polynucleotide of claim 1.

### Claim 16 (depends on 1)

A method for preparing a recombinant polynucleotide or a recombinant cell comprising a recombinant polynucleotide by transposition of a transposon such as a Sleeping Beauty transposon, wherein the transposon preferably is the polynucleotide of claim 1, comprising introducing a cofactor selected from the group consisting of
(A) a cofactor capable of depleting a component of the FACT complex selected from the group consisting of SSRP1 and SUPT16H/SPT16;
(B) an inhibitor of cathepsin selected from the group comprising H,S,V, and L;
(C) a cofactor capable of depleting or inhibiting HSP90;
(D) a factor temporally arresting cells cell cycle in cell cycle phase G0/G1, G1/S, or G2/M; and
(E) a factor inhibiting the ubiquitination of PCNA; and
(F) an agent capable of increasing concentration and/or signaling of ATR,
wherein the cofactor preferably is capable of depleting a component of the FACT complex,
into a cell and inducing transposition in said cell, wherein the cofactor is selected from the group comprising a small molecule, an antibody, siRNA and miRNA,
or comprising inducing transposition in a cell or a cell wherein
(AA) said component of the FACT complex; and/or
(BB) said cathepsin; and/or
(CC) said HSP90 is knocked down; and/or
(DD) the cell cycle is temporally arrested in cell cycle phase G0/G1, G1/S, or G2/M; and/or
(EE) the ubiquitination of PCNA is inhibited; and/or
(GG) concentration and/or signaling of ATR is increased .

### Claim 17 (depends on 9)

The kit of claim 9, wherein the Sleeping Beauty transposase is hyperactive transposase SB 100X.

### Claim 18 (depends on 10)

The method of claim 10, wherein the Sleeping Beauty transposase is hyperactive transposase SB100X.

### Claim 19 (depends on 11)

The method of claim 11, wherein the Sleeping Beauty transposase is hyperactive transposase SB100X.
